In­di­v­ior fails to es­cape class ac­tion law­suit in Sub­ox­one case

In­di­v­ior isn’t get­ting out of its class ac­tion Sub­ox­one law­suit with­out a tri­al, a fed­er­al judge ruled on Mon­day.

Judge Mitchell Gold­berg of Penn­syl­va­nia de­nied two mo­tions by In­di­v­ior for a sum­ma­ry judg­ment in a case al­leg­ing the com­pa­ny com­mit­ted a “prod­uct hop” scheme to pre­vent gener­ic com­pe­ti­tion to its opi­oid ad­dic­tion treat­ment Sub­ox­one.

Sub­ox­one, a com­bi­na­tion of buprenor­phine and nalox­one, was ap­proved in tablet form back in 2002 for the treat­ment of opi­oid de­pen­dence. In­di­v­ior, for­mer­ly a di­vi­sion of Reckitt Benckiser, de­vel­oped the drug along with the Unit­ed States Na­tion­al In­sti­tute on Drug Abuse, and re­ceived or­phan drug ex­clu­siv­i­ty un­til Oc­to­ber 2009.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.